contentSlug

type

ContentSlug_ContentQuery

slug

ContentPageContentQuery

content

trendingContent

query ContentSlug_ContentQuery(
  $contentSlug: String!
  $type: [ContentType!]
) {
  ...ContentPageContentQuery_13QmVO
}

fragment CompanyDetails_Content on Content {
  __isContent: __typename
  companies {
    name
    description
    pageUrl
    id
  }
}

fragment ContentBasicInfo on Content {
  __isContent: __typename
  id
  type
  title
  lang
  companies {
    viewerIsFollowing
    id
    name
    pageUrl
  }
  tags {
    viewerIsFollowing
    id
    name
    pageUrl
  }
  ...PublishingDetails
  ...Reactions
}

fragment ContentMetadata on Content {
  __isContent: __typename
  type
  title
  lang
  pageUrl
  alternatePageUrls: translations {
    __typename
    pageUrl
    lang
  }
  imgUrl
  description
  ... on Video {
    liveTime
    videoUrl
  }
  ... on Webcast {
    liveTime
    videoUrl
  }
}

fragment ContentPageContentQuery_13QmVO on Query {
  content(slug: $contentSlug, type: $type) {
    __typename
    id
    type
    title
    isPremium
    lang
    htmlBody
    summary
    companies {
      forum {
        latestPosts {
          ...ForumPosts
        }
      }
      name
      id
      viewerIsFollowing
      pageUrl
      defaultInstrument {
        isin
        id
        marketOpen
        marketClose
        marketplace {
          region
        }
        returns {
          total
        }
      }
    }
    tags {
      viewerIsFollowing
      id
      name
      pageUrl
    }
    createdAt
    ... on Video {
      liveTime
    }
    ... on Webcast {
      liveTime
    }
    slug
    ... on CompanyReport {
      reportUrl
    }
    ... on ThirdPartyCompanyReport {
      reportUrl
    }
    ... on StockExchangeRelease {
      reportUrl
    }
    ...ContentBasicInfo
    ...ContentMetadata
    ...PriceAndRecommendation_Content
    ...CompanyDetails_Content
    ...ReportLink_Content
    ...KeyFigures_Content
  }
  ...TrendingContent_1jQ2Cn
}

fragment ForumPosts on ForumPost {
  text
  likesCount
  url
  author
  postedAt
  authorImgUrl
}

fragment KeyFigures_Content on Content {
  __isContent: __typename
  companies {
    defaultInstrument {
      estimateData {
        modelType
        reportingCurrency
      }
      snapshot {
        transaction {
          date
          actualized {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
          }
          estimates {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
          }
        }
      }
      id
    }
    id
  }
}

fragment PriceAndRecommendation_Content on Content {
  __isContent: __typename
  createdAt
  companies {
    name
    pageUrl
    defaultInstrument {
      priceData {
        tradeCurrency
      }
      snapshot {
        priceData {
          date
          lastPrice
          tradeCurrency
        }
        transaction {
          date
          recommendation
          targetPrice
        }
        prevTransaction {
          recommendation
        }
      }
      id
    }
    id
  }
}

fragment PublishingDetails on Content {
  __isContent: __typename
  createdAt
  publishers {
    name
    imgUrl
  }
  authors {
    __typename
    id
    name
    slug
    imgUrl
    jobTitle
  }
  ... on Video {
    liveTime
  }
  ... on Webcast {
    liveTime
  }
}

fragment Reactions on Content {
  __isContent: __typename
  id
  reactionGroups {
    reactionType
    reactionsCount
    viewerReacted
  }
}

fragment ReportLink_Content on Content {
  __isContent: __typename
  type
  isPremium
  ... on CompanyReport {
    reportUrl
  }
  ... on ThirdPartyCompanyReport {
    reportUrl
  }
  ... on StockExchangeRelease {
    reportUrl
  }
}

fragment TrendingContent_1jQ2Cn on Query {
  trendingContent(type: ARTICLE) {
    __typename
    id
    title
    lang
    pageUrl
    createdAt
    type
    imgUrl
    companies {
      squareLogoUrl
      name
      id
    }
    authors {
      __typename
      imgUrl
      id
    }
    publishers {
      imgUrl
    }
  }
}


promising-results-farons-bexmab-blood-cancer-study

__typename

title

isPremium

lang

htmlBody

summary

companies

createdAt

publishers

authors

reactionGroups

pageUrl

translations

imgUrl

description

Analyst

Atte Riikola

Faron is a global, clinical-stage biopharmaceutical company, focused on tackling cancers via novel immunotherapies. Its mission is to bring the promise of immunotherapy to a broader population by uncovering novel ways to control and harness the power of the immune system. The Company's lead asset is bexmarilimab, a novel anti-Clever-1 humanized antibody, with the potential to remove immunosuppression of cancers through reprogramming myeloid cell function. Bexmarilimab is being investigated in Phase I/II clinical trials as a potential therapy for patients with hematological cancers in combination with other standard treatments.

It’s still available from there, at least for me. But what exactly is incorrect now? The table clearly compares TD→TI data to the baseline in both places. Where exactly did you draw the conclusion that 4 do not belong to the baseline TD group? Why then compare 4/7? Or next to it, r/r TD baseline 23 and TD-TI 3/23? Or are you claiming that even here, that 3 does not belong to the original TD baseline 23? If the denominator for both is x/7 (==baseline) and y/23 (==baseline), then it’s probably just a TD-TI conversion comparison made against the baseline. Otherwise, the denominators against which the comparison is made would not match the baseline. From this, a total of 7 baseline TD→TI cases were then modeled on swimlane charts to visualize the TD→TI change.

Faron should definitely come out and clarify these discrepancies and/or ambiguities in plain language. I find it hard to believe that they have tried to deceive the whole world. It’s easy to fool the forum crowd, but I imagine many external experts would have raised an alarm if the data had been distorted.

In 1st line, 7 patients had Baseline TD. 4 1st line and 3 r/r patients achieved a TD-TI response during treatment. These 4 are not part of that group of 7 baseline TD patients! The announcement is factually incorrect. No wonder the poster has been removed. Quickly save it from the forum.

The press release states: “For the first time, data shows 57% of frontline patients who were transfusion-dependent at baseline achieved transfusion independence, confirming restoration of healthy bone marrow function.” In the ASH poster: “In treatment-naïve HR MDS, 57% of baseline TD patients became TI with BEX+AZA.” I don’t really understand much of this, but do you really think this is incorrect information? Because I noticed that the poster I linked earlier has been removed from Faron’s website.

WOW. It was good that this figure was looked at more closely. The 57% figure is on-treatment TD-TI, not baseline TD-TI. Medically, these are completely different things. Look at the wording of the poster, the swimlanes. This explains the difference from the publication and the abstract. Faron unequivocally provides misleading information in the press release. This is indeed a red flag!

Ok  We did not get the background for these nor the Kaplan-Meier. Likely a very heterogeneous dataset, and my concern about early censoring still persists.  So, as I said above, this is an investigator-assessed figure, meaning it’s biased, and central assessment does not reach the same figures, because for the entire first-line, it is 30% as Zeidan now told us.  Treatment response does not primarily determine whether a bone marrow transplant is performed. See HR MDS treatment guidelines. Deep response likely refers to MRD figures, the definition method of which is unknown, hence the NGS vs. flow cytometry difference here.  It seems to be on par with aza, if healthier patients are treated. See Bexmab inclusion and exclusion criteria. Edit: it is still clearly higher than expected with aza, even considering patient selection. It’s worth digging up that Kontro poster and seeing how this result was obtained. Edit2: In Kontro’s publication 11/2025 completely different figures, TD-TI in treatment-naïve patients 17%. I don’t have the energy to try and understand how the difference can be this large right now. In all results, the small sample size and the resulting confidence intervals should be noted.

https://ashpublications.org/blood/article/doi/10.1182/blood.2025029727/548015/The-conundrum-of-drug-development-in-higher-risk I won’t bother, I’ll just quote smarter people. Here’s a recent publication by our esteemed Professor Zeidan. It costs a hundred. At the end, a tabulation of recent MDS trials and their responses.

Faron Pharmaceuticals

On Wednesday, Faron Pharmaceuticals published new positive results from the BEXMAB study to examine the efficacy of the company's precision immunotherapy treatment (bexmarilimab) for a number of malignant haematological tumors, or blood cancers. 

Translation: Original comment published in Finnish on 7/19/2023 at 6:40 am. On Wednesday, Faron Pharmaceuticals <a href="https://www.inderes.se/releases/faron-pharmaceuticals-oy-bexmab-study-update-4">published</a> new positive results from the BEXMAB study to examine the efficacy of the company's precision immunotherapy treatment (bexmarilimab) for a number of malignant haematological tumors, or blood cancers. Faron also stated that they plan to file the first Biologics License Application (BLA) to FDA in H1’25. According to the company, the data received so far in the study supports moving to clinical Phase II. This move is already included in our modeling as a very likely scenario in our estimates. So there is no need for major estimate changes, but we will review our assumptions in connection with our Q2 pre-comment. Our latest update on Faron is available <a href="https://www.inderes.se/research/faron-pharmaceuticals-bexmab-studys-good-momentum-supports-valuation">here.</a>

	2022	23e	24e
Revenue	0.0	0.0	0.0
growth-%
EBIT (adj.)	-27.4	-15.8	-3.1
EBIT-% (adj.)	-685,650.0 %	-394,522.5 %	-76,864.0 %
EPS (adj.)	-0.48	-0.25	-0.05
Dividend	0.00	0.00	0.00
Dividend %
P/E (adj.)	neg.	neg.	neg.
EV/EBITDA	neg.	neg.	neg.

Promising results from Faron's BEXMAB blood cancer study

Key Estimate Figures2023-04-17

Forum discussions